|
|
 |
|
Viewing report
|
|
|
|
Medicated Skin Products Market in Finland to 2014 (OTC Healthcare)
Datamonitor, Feb 2011, Pages: 28
Introduction
This databook provides key data and information on the Medicated Skin Products Market in Finland (OTC Healthcare). This report is a comprehensive resource for market, category and segment level data including value, volume, distribution share and company & brand share. This report also provides expenditure and consumption data for the historic and forecast periods.
Scope
-Market,category and segment level information on value, volume, and expenditure & consumption, with historic (2003-2008) and forecast (2009-2013) data
-Category level company and brand share as well as distribution share information for 2007 and 2008
Highlights
The medicated skin products category was valued at €31.4m ($46m) in 2009, representing a CAGR of 6.8% since 2004.
By the end of 2014, the medicated skin products category will be worth €30.4m ($44.5m), with an expected negative CAGR of 0.7% between 2009 and 2014.
The medicated skin products market was led by anti-fungals (representing 61.4% of the total value) followed by anti-bacterials and acne treatments, with a 19.6% and 12.7% market share, respectively. Disinfectants accounts for the remaining 6.2% share.
GlaxoSmithKline Plc is the market leader with a 26.2% share of the market.
Reasons to Purchase
-Develop business strategies by understanding the quantitative trends within the Medicated Skin Products Market in Finland (OTC Healthcare)
-Design effective marketing and sales strategies by identifying key market categories and segments
-Identify key players within the market to plan lucrative M&A, partnerships and agreements
|
|
|
|
